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Classification 
Intraocular eye cancer diagnosis is based on ophthalmic 
examination, patient history, A/B scan ultrasonography, 
fluorescein and indocyanine green angiography, and 
optical coherence tomography. Ocular tumors can be 
generally divided into the categories that appear blow. 
These cancers can arise in children or adults. 
I. Intraocular tumors of childhood 
A. Retinal tumors 
-1. Retinoblastoma 
B. Iris and ciliary body lesions 
-1. Medulloepithelioma 
C. Choroidal and RPE lesions 
-1. Congenital hypertrophy of the retinal pigment 
epithelium 
-2. Combined hamartoma of the retina and retinal 
pigment epithelium 
-3. Congenital melanocytosis 
D. Other benign tumors 
II. Intraocular tumors in adults 
A. Choroidal and RPE lesions 
-1. Choroidal nevus 
-2. Choroidal melanoma 
B. Iris and ciliary body lesions 
-1. Fuchs adenoma 
-2. Iris nevus 
-3. Ciliary body nevus 
-4. Iris melanoma 
-5. Ciliary body melanoma 
C. Metastatic disease to the choroid 
III. Vascular tumors 
A. Retinal capillary hemangioma 
B. Retinal cavernous hemangioma 
C. Choroidal hemangioma 
 
Clinics and pathology 
Note 
Intraocular tumors vary significantly in epidemiology, 
etiology, pathology, and treatment methods. As a 





Traditionally, retinoblastoma was believed to come in a
germinal and non-germinal form, both of which result 
from a mutation or loss of both alleles of the 
retinoblastoma gene (RB1). In germinal cases, the first 
mutation is in the germline and the second is somatic. 
In the non-germinal form, both mutations are somatic 
resulting in unilateral and unifocal lesions. Recent data 
suggests that all patients with retinoblastoma exprss a 
degree of mosaicism. (Sippel et al., 1998). 
Epidemiology 
With a lifetime incidence rate ranging between one in 
18000 to 30000 live births, the most common primary 
ocular malignancy of childhood is a rare tumor. The 
etiology of this tumor seems to be minimally affected 
by environment, which is shown by the surprisingly 
similar incidence rates among several populations of 
the world. The median age of diagnosis in the United 
States is 18 months, with the median age for unilateral 
cases being 24 months and the median age for bilateral 











Atlas Genet Cytogenet Oncol Haematol. 2011; 15(4)  361 
Group I 
  a. Solitary tumor, less than 4 disc diameters in size, at or behind the equator 
  b. Multiple tumors, none over 4 disc diameters in ize, all at or behind the equator 
Group II 
  a. Solitary tumor, 4 to 10 disc diameters in size, at or behind the equator 
  b. Multiple tumors, 4 to 10 disc diameters in size, behind the equator 
Group III 
  a. Any lesion anterior to the equator 
  b. Solitary tumors larger than 10 disc diameters behind the equator 
Group IV 
  a. Multiple tumors, some larger than 10 disc diameters 
  b. Any lesion extending anteriorally to the ors seratta 
Group V 
  a. Massive tumors involving over half the retina 
  b. Vitreous seeding 
Table 1: Reese-Ellsworth scheme for intraocular retinoblastoma 
Group A Rb ≤ 3 mm in basal dimension or thickness 
Group B Rb > 3 mm or with one or more of the following: 
  - Macular location (≤ 3 mm to foveola) 
  - Juxtapapillary location (≤ 1.5 mm to optic nerve) 
  - Additional subretinal fluid (≤ 3 mm from margin) 
Group C Retinoblastoma tumor with one of the following: 
  - Subretinal seeds ≤ 3 mm  
  - Vitreous seeds ≤ 3 mm 
  - Both subretinal and vitreous seeds ≤ 3 mm  
Group D Retinoblastoma tumor with one of the following: 
  - Subretinal seeds > 3 mm  
  - Vitreous seeds > 3 mm 
  - Both subretinal and vitreous seeds > 3 mm  
Group E Extensive retinoblastoma occupying > 50% of gl be or any of the following: 
  - Neovascular glaucoma 
  
- Opaque media from vitreous hemorrhage in anterior chamber, vitreous, or subretinal 
space 
  - Invasion of postlaminar optic nerve, choroid (> 2 mm), sclera, orbit, or anterior chamber 
Table 2: New international classification for retinoblastoma 
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Clinics 
The most common presenting symptom of patients with
retinoblastoma in developed nations is leukocoria, 
which is a reflection of incoming light off of the tumor. 
Retinoblastoma is diagnosed ophthalmoscopically, but 
ultrasound and fundus photography should also be don
to confirm the diagnosis. Ultrasound typically 
demonstrates a mass with high reflectivity and 
intralesional calcium causing shadowing behind the 
tumor. 
Staging: The Reese-Ellsworth classification has been 
the predominant system used since its development in 
the 1960's as a way to predict prognosis in patients 
treated with external beam radiation (Table 1) (Reese, 
1976). Because of the decreasing use of external beam 
radiation for intraocular retinoblastoma, a new 
international classification system has been developed 
with subgroups ranging from disease that is most eaily 
treated by chemotherapy and focal treatments to 
disease that is least easily treated by these methods 
(Table 2) (Murphree, 2005). The exclusive use of the 
new classification system makes comparisons with 
older series more difficult. Consequently, many authors 
will continue to include the Reese-Ellsworth 
classifications. 
Pathology 
Retinoblastomas are characterized histopathologically 
by basophilic cells with minimal cytoplasm 
surrounding a lumen in a rosette formation or radially 
arranged around a central tangle of fibrils in a 
pseudorosette formation. Often times, necrosis and 
hemorrhage are present within the tumors, as they tend
to outgrow their vascular supplies. 
 
Endophytic retinoblastoma lesion in the right eye obscuring the 
view of the macula and optic disc. 
Cytogenetics 
Linkage analysis and deletion techniques discovered 
the RB1 to be localized to chromosome 13q14 (Yunis 
and Ramsay, 1978). The gene spans 180 kb, is  
composed of 27 exons, and encodes a 4.8 kb mRNA 
transcript that is expressed in all human tissues. The
resulting protein product is a 110 kD nuclear 
phosphoprotein, consisting of 928 amino acids. 
Genes 
The RB1 gene encodes a protein that is a regulator at 
the major checkpoint of the cell cycle, between the G1 
and S-phase. In its normal non-phosphorylated form, 
the retinoblastoma protein (pRB) binds to 
transcriptional factors, like E2F, to prevent entry into 
the S-phase. The phosphorylated form of pRB 
dissociates from E2F, which allows the transcription 
factor to bind DNA and promote progression through 
the cell cycle. Abnormal RB1 function allows for 
continuous entry into the S-phase and rapid cell 
division, which causes tumor formation. (Hernando et 
al., 2004). 
Treatment 
Treatment of retinoblastoma is often performed in a 
multi-modal approach including enucleation, external 
beam radiation, chemotherapy, transpupillary 
thermotherapy, cryotherapy, and brachytherapy. 
Chemotherapy has been the most widely used treatment 
for retinoblastoma since the mid-1990's when extensiv  
research showed an increased risk in secondary tumors 
in survivors of germinal retinoblastoma treated with 
external beam radiation. The dosing regimens, 
schedules, and chemotherapeutic agents vary 
significantly among oncology centers, but the most 
common includes carboplatin, etoposide and 
vincristine. Most centers use chemotherapy to reduc 
the tumors, which allows focal treatment like laser and 
cryotherapy to be more effective. Enucleation is stll
used in very advanced cases. Some centers use 
periocular carboplatin with systemic chemotherapy to 
salvage globes with advanced disease. Anti-angiogenc 
agents and intra-arterial chemotherapy infusions are 
also currently being investigated. 
Prognosis 
The most significant factor leading to death is 
extraocular invasion by the tumor, with a considerable 
delay in initial diagnosis also contributing to a reduced 
likelihood of survival. The overall 5 to 10 year survival 





Medulloepithelioma is a tumor that arises from the 
epithelium of the medullary tube, most often the ciliary 
body. It can take a teratoid or nonteratoid form and 
usually presents itself as a unilateral congenital disease, 
although bilateral, juvenile, and adult-onset cases have 
also been reported. (Broughton and Zimmerman, 
1978). 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(4)  363 
Epidemiology 
Medulloepithelioma is a rare tumor with an incidenc 
of 1 case per 450000 - 1000000 people (Augsburger 
and Schneider, 2004). Medulloepithelioma has no 
racial and gender predilection, has no clear pattern of 
inheritance, and no identifiable risk factors. The m an 
age at diagnosis is 4 - 5 years. 
Clinics 
It most commonly presents as a gray-white lesion of 
the anterior chamber angle, but can present as a diffuse 
mass causing leukocoria (Broughton and Zimmerman, 
1978). Neovascular glaucoma in a child with a normal 
posterior segment, iris notching, and an unexplained 
cyclitic membrane are features that may assist in 
diagnosis. While clinical examination may be sufficient 
to diagnose medulloepithelioma, ultrasound can be a 
useful adjunct as it demonstrates cystic spaces and a 
lack of calcifications. (Foster et al., 2000). 
Pathology 
Histopathologic analysis reveals a tumor composed of 
epithelium that can be arranged in cords and sheets 
separated by cystic spaces containing proteinaceous 
material. Teratoid forms contain heterotopic elements 
including skeletal muscle and cartilage. Malignant 
tumors often have areas consisting of poorly 
differentiated neuroblastic cells, increased mitotic 
activity, sarcomatous areas, and tumor invasion of 
other ocular tissue, regardless of extraocular extension. 
(Broughton and Zimmerman, 1978). 
 
Medulloepithelioma with opaque white lesion. 
Treatment 
Currently, there is not a definitive treatment for 
medulloepithelioma. Observation is often 
recommended for smaller tumors without sequellae. 
Primary enucleation is recommended if the tumor is 
large, there is extrascleral extension, the eye is blind 
and painful, or there is neovascular glaucoma. Local 
resection and invasive diagnostic procedures should be 
avoided as they may lead to recurrence, direct seeding  
of the orbit, or creation of a tract for subsequent tumor 
migration from the globe and into the orbit. (Shields et 
al., 1996). 
Prognosis 
The natural history of untreated medulloepitheliomas is 
essentially unknown. Metastasis in medulloepithelioma 
is very rare, but portends a more negative prognosis 
when present. Only lesions with malignant features 
metastasize, but neither teratoid features nor malign nt 
morphology predict mortality. While there has been no 
reported deaths or metastases in patients who undergo 
definitive enucleation without prior diagnostic invasive 
procedures, patients who have had prior invasive 
procedures are thought to have a higher mortality rate. 
(Canning et al., 1988). 
Disease 
Congenital hypertrophy of the retinal pigment 
epithelium (CHRPE). 
Note 
An association in the literature has been made between 
familial adenomatous polyposis (FAP) and CHRPE-
like lesions. FAP is a syndrome with an autosomal 
dominant mode of inheritance that causes the 
development of hundreds of pre-malignant colonic 
polyps and is caused by a mutation in the APC gene 
located on chromosome 5q21. The lesions have also 
been described in instances of Gardner's and Turcot's 
syndrome. Gardner's syndrome consists of FAP 
associated with soft-tissue tumors and skeletal growths, 
while Turcot's syndrome consists of APC associated 
with tumors of the central nervous system. The ocular 
manifestations associated with FAP, Gardner's, and 
Turcot's syndrome have been labeled as pigmented 
ocular fundus lesions (POFLs) in order to differentiate 
them from CHRPE lesions. Not only are POFLs 
bilateral, numerous, and pisciform in shape, but they 
also differ from CHRPE lesions histopathologically as 
they are shown to have hamartomatous changes in 
addition to RPE hypertrophy and hyperpigmentation. 
(Parsons et al., 2005). 
Etiology 
Congenital hypertrophy of the retinal pigment 
epithelium (CHRPE) is an isolated sporadic congenital 
lesion with no known underlying genetic basis. 
Epidemiology 
While the prevalence of CHRPE is unknown because it 
usually presents asymptomatically, one study 
demonstrated a prevalence of 1.2% (Coleman and 
Barnard, 2007). Age is not a relevant factor in the
development of CHRPE because it is a congenital 
lesion, but studies have shown a median age of 
diagnosis to be 45 (Shields et al., 2003). Studies 
suggest Caucasians are more likely to demonstrate 
CHRPE (Shields et al., 2003). 
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Clinics 
Because CHRPE are most commonly found in the 
peripheral retina, patients are commonly asymptomatic 
and present with round, darkly pigmented, flat lesion  
that can be surrounded by a hypopigmented halo 
(Lloyd et al., 1990). Lacunae, atrophied window-like 
defects, are present in about 50% of CHRPE lesions 
(Shields et al., 2003). Fundoscopic examination 
showing classical features of the lesion are sufficient 
for diagnosis, and no further ancillary studies are 
needed. 
Pathology 
Histopathologically, CHRPE lesions show 
hypertrophied RPE cells that contain excessive pigment 
granules resembling melanin without lipofuscin 
(Parsons et al., 2005). The overlying photoreceptor 
layer may be atrophic, while the underlying choroid 
and choriocapillaris are usually normal. There may be 
RPE dropout or reduced pigmentation in areas of 
lacunae, and glial cells are present between Bruch's 
membrane and the RPE in these areas (Parsons et al.,
2005). 
 
Congenital hypertrophy of the retinal pigment epithelium located 
in the superotemporal quadrant of the right eye. Note the flat, 
round, and darkly pigmented classical appearance of the lesion. 
Treatment 
Treatment is usually unnecessary except for the rar
instance in which neovascularization presents at the 
periphery of the lesion. 
Prognosis 
CHRPE are benign lesions that show minimal growth 
in up to 80% of cases, and usually do not cause visual 
disturbances (Shields et al., 2003). On a rare occasion, 
CHRPE may transform to malignant adenocarcinoma, 
but the etiology and most appropriate management has 
yet to be determined (Shields et al., 2009). 
Disease 
Combined hamartoma of the retina and retinal pigment 
epithelium (RPE). 
Etiology 
Combined hamartoma of the retina and retinal pigment 
epithelium (RPE) is a rare developmental disorder 
caused by benign proliferations of both the retina a d 
RPE. There may be a systemic association with 
neurofibromatosis type I and neurofibromatosis type II 
(Palmer et al., 1990; Kaye et al., 1992), but the 
mechanistic relationship has not yet been established. 
They are considered to be congenital lesions in most 
instances but acquired lesions have been reported 
infrequently (Ticho et al., 1998). 
Epidemiology 
The prevalence of this occurrence has not been 
established, but whites have been shown to be more 
frequently affected (Shields et al., 2008). Two major 
studies have shown a mean age of diagnosis 15-18 
years (Font et al., 1989; Schachat et al., 1984), and 
there may be a slight predilection for males (Font et al., 
1989). 
Clinics 
Classically, combined hamartomas present as 
unilateral, dark, solitary lesions that are slightly 
elevated with varying amounts of retinal and epiretinal 
tissue centrally causing progressive traction and 
vascular tortuosity (Font et al., 1989). They are located 
in the macular and extramacular region at equal 
frequencies (Shields et al., 2008). Indirect 
ophthalmoscopy is often sufficient for diagnosis, but 
fluorescein angiography (FA) is a useful adjunct as it 
shows blocking of choroidal perfusion and progressive 
hyperfluorescence in the late phase (Schachat et al., 
1984). 
Pathology 
Histopathologically, combined hamartomas 
demonstrate infiltration of hyperplastic RPE into the 
retina and inner retinal surface. Gliosis is significant 
and is responsible for the tractional changes and 
vascular tortuosity. (Vogel et al., 1969). 
Treatment 
While most cases of combined hamartoma are isolated 
from systemic findings, patients who have been 
diagnosed should undergo evaluation to exclude 
neurofibromatosis. Amblyopia therapy has been shown 
to improve vision in some patients with combined 
hamartoma (Schachat et al., 1984). Vitrectomy and 
membrane removal has been performed, but the visual 
acuity does not always improve significantly and 
membranes may recur (Shields et al., 2008). 
Consequently, the role of vitrectomy in managing  
combined hamartoma has not been fully established. 
Rarely, choroidal neovascularization may occur as a 
complication and can be treated with laser. 
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Combined hamartoma of the retina and retinal pigment 
epithelium positioned on the optic disk and adjacent retina with 
a predominantly glial component. A, Color fundus photography 
with peripheral areas of traction corresponding to the posterior 
hyaloid face. B, Fluorescein angiography of the lesion in the 
same patient demonstrating the striking vascular abnormalities. 
Prognosis 
Combined hamartoma can cause significant visual loss, 
with a visual acuity <20/200 in up to 40% of patiens 
(Schachat et al., 1984). Vision loss usually occurs as a 
result of involvement of the optic nerve or macula, but 
may also be associated with traction from an epiretinal 
membrane. Macular involvement occurs in about 50% 
of the lesions and continued vision loss over time is 





Ocular melanocytosis is a congenital 
hyperpigmentation of the globe caused by increased 
numbers of melanocytes. One study shows that the 
hyperpigmentation of ocular melanocytosis is primarly 
congenital as it was documented in 85% of patients at 
birth (Teekhasaenee et al., 1990). There is often dermal 
involvement due to the failure of melanocytes of neural 
crest cell origin to reach the intended surface position , 
which gives rise to hamartomatous nests in the 
distribution of the first and second branches of the
trigeminal nerve (Zaihosseini et al., 2008). 
Epidemiology 
Ocular melanocytosis is an uncommon condition with a 
prevalence rate of 0.038% in the white population, 
0.014% in the black population, and between 0.4 and 
0.84% in the Asian population (Gonder et al., 1982). 
There are no differences in frequency based on 
laterality or gender. 
Clinics 
Characterized by melanotic pigmentation of the iris, 
patches of gray-brown scleral pigmentation, and 
ipsilateral choroidal hyperpigmentation (Rahman et al., 
2008). There may or may not be involvement of the 
periorbital facial tissues in the distribution of the 
trigeminal nerve. Diagnosis is based on presentation 
with classic findings noted during slit-lamp 
examination. 
Pathology 
Histopathologically, ocular melanocytosis is 
characterized by the presence of dendritic melanocytes 
in the areas of hyperpigmentation. 
 
Congenital melanocytosis revealing gray-brown 
hyperpigmentation of the sclera and periorbital area of the right 
eye. 
Treatment 
In and of itself, congenital ocular melanocytosis is a 
benign condition that does not require treatment. 
However, in the white population there has been shown 
to be a lifetime risk of developing uveal melanoma of 1 
in 400, which is significantly greater than the 1 in 
13000 risk observed without underlying congenital 
melanocytosis (Shields et al., 1991). Because of the 
association with uveal melanoma, annual ophthalmic 
follow-up is recommended for all patients with ocular 
melanocytosis (Rahman et al., 2008). 
Prognosis 
Visual impairments that arise in the context of ocular 
melanocytosis are due to the development of 
complications including uveitis, glaucoma, and 
cataract. Additionally, the association with an increased 
frequency of uveal melanoma in the affected eye, has 
further implications on morbidity and mortality. 
(Gonder et al., 1982). 










Uveal nevi are stromal, hamartomatous clusters 
consisting of atypical melanocytes of neural crest 
origin much like cutaneous melanocytes. They have 
been described predominantly in three locations 
including the iris, ciliary body, and choroid. 
Epidemiology 
Iris nevi are found in about 4 to 6% of the population 
(Harbour et al., 2004), while ciliary body nevi are 
infrequently reported. Choroidal nevi have a reported 
prevalence rate that ranges from 0.2% to 30% 
depending on the population (Shields et al., 1995) and 
are rarely found in blacks. They often become 
pigmented or develop within the first three decades of 
life, and there is no conclusive data to show an 
association with gender. 
Clinics 
Iris nevi are typically solitary, circumscribed lesions 
located in the lower quadrants of the iris, ranging from 
tan to dark brown. Ciliary body nevi present as dome-
shaped masses without intrinsic vascularity. Diagnosis 
of both iris and ciliary body lesions can often be made 
based on anterior segment evaluation with gonioscopy. 
Ultrasound biomicroscopy assists in diagnosis by 
determining size, extent and solid or cystic consistency 
(Conway et al., 2005). Choroidal nevi usually do not
cause symptoms and present as grayish brown lesions 
with minimal thickness, and diagnosis can be made by 
ophthalmoscopy. 
Pathology 
Nevi are known to consist of four different cell types 
including plump polyhedral, slender spindle, 
intermediate, and balloon cells. Posteriorly, choroidal 
nevi have been shown to involve full thickness of the
choroid with sparing of the choriocapillaris. (Naumann 
et al., 1966). 
 
Pigmented choroidal nevus situated temporal to the macula 
with overlying drusen. 
Treatment 
Periodic ophthalmic examination for nevi to check for 
growth or malignant progression is recommended for 
nevi in all locations. For choroidal nevi, follow-up is 
especially important if the nevi cause decreased vision 
or visual field defects or have high-risk characteris ics 
such as thickness greater than 2mm, posterior location, 
orange pigment, subretinal fluid, and absence of drusen 
(Singh et al., 2005; Singh et al., 2006). 
Prognosis 
The prognosis for all forms of nevi tends to be good 
with iris nevi showing enlargement in less than 5% of 
cases (Territo et al., 1988). For choroidal nevi, the rate 
of transformation to melanoma is significantly less than 
1%, which means that the majority of patients with nevi 





Uveal melanoma is the most common primary 
intraocular malignant tumor, and they originate from 
the iris, ciliary body, or choroid. The majority ofthese 
tumors arise in the choroid, and the predisposing 
factors include family history of choroidal melanoma, 
dysplastic nevus syndrome, xeroderma pigmentosum, 
and congenital ocular melanocytosis. While some arise 
de novo (Sahel et al., 1988), there is clinical and 
histopathologic evidence that many originate from pre-
existing, benign nevi (Naumann et al., 1966). Exposure 
to sunlight has been postulated to have an effect, but 
there is no convincing evidence of a causative 
relationship (Shah et al., 2005). 
Epidemiology 
Choroidal melanomas are found most often in countries 
with large populations of people of northern European 
decent. Caucasians are 19 times more likely to have 
choroidal melanoma than African Americans and 16 
times more likely than Asians (Hu et al., 2005). While 
there is wide age variation in melanoma patients, 65% 
are over the age of 50. Men and women are equally 
affected, and there is no predilection for either eye. 
Clinics 
Patients with both iris and ciliary body melanomas may 
present without symptoms, or may have glaucomatous 
changes or cataract progression as a result of the tumor. 
Diagnosis can often be made from slit-lamp 
examination and gonioscopy, but ultrasound 
biomicroscopy is useful to guide therapy. Choroidal 
melanomas are also usually found on routine 
examinations in asymptomatic patients, but they may 
cause decreased visual field and acuity. 
Ophthalmoscopy is typically adequate for diagnosis, as 
the lesions tend to have a dome or mushroom shaped  
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appearance that often protrudes into the vitreous. 
Ultrasound and FA can be used to aid in diagnosis, 
with ultrasound classically showing an elevated solid 
tumor with low to medium internal reflectivity and 
significant vascularity. (Coleman et al., 1974). 
Staging: While melanomas lack discrete clinical and 
pathological stages, new evidence indicates that they
can be classified into distinct molecular classes that are 
strongly associated with metastatic risk. These classes 
are based on gene expression profile with class 1 
representing low-grade and class 2 representing high-
grade tumors. Class 2 tumors demonstrate down-
regulated gene clusters on chromosome 3 and up-
regulated gene clusters on chromosome 8q. A Kaplan-
Meier based analysis showed survival prediction of 
95% in class 1 and 31% in class 2 at 92 months. 
(Onken et al., 2004). 
Pathology 
Spindle A, spindle B and epithelioid are the three c ll
types found in melanomas. The Callender classification 
divides these tumors by histopathologic type into 
spindle cell, mixed-cell and epithelioid cell tumors, 
with a poorer prognosis for survival in tumors that ve 
a higher proportion of epithelioid cells (Mclean et al., 
1983). However, this classification can only be used in 
cases in which the eye has been removed. 
 
Large, elevated inferior choroidal melanoma with both 
melanotic and amelanotic components. Note the overlying 
retinal detachment located in the inferonasal quadrant. 
Cytogenetics 
Multiple chromosomal abnormalities have been 
detected in uveal melanoma tissues and associated with 
metastasis, including gain or loss of chromosomal 
material in chromosomes 3, 6, and 8 (Sisley et al., 
1990). Monosomy 3 is a predictor of increased risk of 
relapse and mortality (Prescher et al., 1996). Studies 
have shown as many as 57% of patients with 
monosomy 3 developed metastasis, while no patients 
with disomy 3 developed metastatic disease within 3 
years (Prescher et al., 1996). 
Treatment 
The Collaborative Ocular Melanoma Study (COMS) 
divided choroidal melanomas into small, medium and 
large tumors in order to identify the best treatment 
modality for each (Karlsson et al., 1989). Observation 
is often the primary management for small tumors, 
particularly if they do not show high-risk 
characteristics, but they can be treated with 
transpupillary thermotherapy (TTT) or brachytherapy 
(Robertson et al., 1999; Sobrin et al., 2005). Medium 
sized tumors are treated by brachytherapy, which 
shows equivalent survival rates as enucleation (Diener-
West et al., 2001). Large tumors are most often treated 
with enucleation alone, but treatment with 
brachytherapy may be reasonable as recent studies 
suggest similar survival rates to those in patients treated 
with enucleation. 
Prognosis 
Analysis of choroidal melanoma has determined 
various mortality rates based primarily on tumor size 
and treatment used. The COMS showed a 1% 
melanoma-specific mortality rate for small tumors 
(COMS group, 1997), but it is important to note that 
this study included a large number of suspected tumors 
that did not grow and were never treated. Medium-
sized melanomas have similar 5-year melanoma-
specific mortality rates after brachytherapy or 
enucleation (19 and 18% respectively) (Diener-West et 
al., 2001). Due to complications after treatment wih 
brachytherapy, 43% of patients have poor vision, 
20/200 or worse, by 3 years of follow-up (Melia et al.,
2006). Large melanomas treated with enucleation aloe 
have a 43% all-cause and 27% melanoma-specific 5-




Fuchs' adenoma is benign, acquired tumor that arises 
from pars plicata of the ciliary body and seems to be 
age-related (Bateman and Foos, 1979). This lesion has 
also been labeled coronal adenoma and age-related 
hyperplasia of nonpigmented ciliary epithelium. 
Epidemiology 
These lesions are not uncommon as they have been 
shown to be found in 14-18% of eyes at autopsy 
(Zaidman et al., 1983). This tumor has an increased 
frequency in older patients, generally found from 50-60 
years. 
Clinics 
Fuchs' adenoma predominantly presents as an 
asymptomatic opaque white mass that can be solitary or 
multiple, unilateral or bilateral and is usually confined 
to 1 ciliary process (Shields et al., 2009). Clinical  
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observation is often enough for diagnosis, but these 
lesions are often misdiagnosed as malignant neoplasms. 
Careful observation is initially important to determine 
the growth pattern, which assists in diagnosis. 
Pathology 
Histopathologically, Fuchs' adenoma are characterized 
by a proliferation of cords of nonpigmented epithelial 
cells surrounded by amorphous periodic acid-Schiff-
positive extracellular material (Zaidman et al., 1983). 
 
Fuchs adenoma located in the anterior chamber angle. 
Treatment 
No treatment is recommended in most cases of Fuchs' 
adenoma as they are benign and nonprogressive.  
Because these lesions may precipitate cataract 
formation, cataract extraction surgery may be required 
(Zaidman et al., 1983). 
Prognosis 
Most often the tumors are found incidentally because of 
small size and location (Bateman and Foos, 1979). As a
result, they tend not to impair visual acuity except in 





Metastasis to the eye most commonly arises from 
primary lung and breast cancer, with many patients 
having no previously diagnosed primary cancer 
(American Academy of Ophthalmology, 2004). 
Epidemiology 
It is estimated that 30000 to 100000 patients with 
cancer develop metastasis to the eye each year, which 
is significantly more than the 350 and 1500 yearly 
cases of retinoblastoma and choroidal melanoma 
respectively (Shields et al., 1997). 
Clinics 
The uveal tract is the most common location for 
metastatic disease in the eye, with choroidal metastasis 
being more common than iris or ciliary body 
metastasis. Ophthalmoscopic examination demonstrate 
classic findings including multiple, bilateral, minimally 
elevated, and amelanotic lesions. Ultrasound is often 
used to confirm diagnosis, showing high internal 
reflectivity. 
 
Large amelanotic choroidal metastasis from a lung 
adenocarcinoma in a patient whose vision recovered to 20/30 in 
this eye after external beam radiation. The patient died 21 
months after diagnosis of the lung cancer, which was 
discovered due to ocular symptoms. 
Treatment 
Treatment of ocular lesions rarely has an impact on 
survival, but may improve the quality of life. It is 
therefore considered in response to decreased vision, 
pain, or diplopia. Treatment options include 
chemotherapy, hormonal manipulation, and external 
beam radiation. 
Prognosis 
With the exception of breast and carcinoid cancer, 
median survival in patients with metastatic choroidal 
lesions is just over 6 months, reflecting the overall 
mortality patterns due to the primary lesion. 
Disease 
Retinal capillary hemangioma 
Etiology 
Retinal capillary hemangioma (RCH) is the earliest and 
most frequent manifestation of von Hippel-Lindau 
(VHL) disease, which is a cancer syndrome with an 
autosomal-dominant mode of inheritance that results 
from mutations in the VHL gene. Between 49-85% of  
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people with VHL have a RCH (Singh et al., 2001a), 
which usually presents as a solitary lesion.  
However, there are multiple RCHs in about one-third 
of patients and bilateral involvement in up to half of 
patients, which are not associated with VHL disease. 
Epidemiology 
Incidence of RCH is estimated to occur 1 in 36000 to 1
in 53000 people. Mean age of VHL diagnosis was 25 in 
patients with retinal involvement (Singh et al., 2001a). 
Non-VHL-associated hemangiomas have a later onset, 
with the mean age of diagnosis being 35 (Singh et al., 
2001b). The accumulation of the tumor phenotype may
be age dependent. 
Clinics 
The classic manifestation of RCH is a round, 
circumscribed, red-orange colored vascular lesion that
is supplied by prominent feeder vessels. The lesion is 
most often located in the peripheral retina but may also 
be seen in the juxtapapillary retina or both locations 
(Wong et al., 2008). Ophthalmoscopic evaluation is 
usually sufficient for diagnosis, but the use of FA is 
particularly helpful because of the vascular nature of 
the tumor. The FA classically shows filling the dilated 
feeder arteriole in the arterial phase followed by filling 
of the draining vein in the venous phase, and the lesion 
itself shows progressive hyperfluorescence with late 
leakage (Singh et al., 2001a). 
Pathology 
Histopathologically, RCHs demonstrate vascular 
channels that are lined by pericytes and endothelial 
cells and are separated by stromal cells. Of the thr e 
cells associated with the tumor, the stromal cells are 
thought to be the neoplastic component (Singh et al., 
2001a). 
 
Retinal capillary hemangioma presenting with the classic 
appearance of a dilated artery feeding the vascular lesion and 
engorged draining vein. 
Cytogenetics 
The VHL gene is located on chromosome 3p25-26 and 
is represented in 3 exons contained in a 20 kb region 
(Singh et al., 2001a). The mutation in the  
VHL gene varies significantly, ranging from a 
substitution of a single amino acid to the deletion of the 
entire gene (Wong and Chew, 2008). The somatic cells
in patients with inherited VHL have a single mutated 
copy of the VHL gene, which is a tumor suppressor 
gene. When a retinal cell acquires a mutation in the 
remaining VHL gene, there is subsequent 
transformation into the tumor phenotype (Wong et al., 
2008). 
Genes 
The VHL protein is responsible for degrading hypoxia 
inducible factors (HIFs), which are produced in 
response to hypoxic conditions and upregulate the 
release of vascular endothelial growth factor and 
platelet-derived growth factor. The increased levels of 
HIFs that occur in the absence of VHL protein function 
subsequently lead to elevated levels of vascular 
endothelial derived growth factor and platelet deriv d 
growth factor, which contribute to tumor formation. 
(Wong and Chew, 2008; Kaelin, 2002). 
Treatment 
Multiple treatment modalities are used in the 
management of RCH. Observation is often the initial 
management for juxtapapillary hemangiomas as 
treatment tends to damage the optic nerve and the 
major retinal vessels leading to permanent visual loss. 
Laser is usually indicated for small lesions located in 
the periphery, while cryotherapy is preferred when the 
tumor is anteriorly located, has a diameter larger than 3 
mm, and associated subretinal fluid large enough to 
cause decreased laser uptake. Transpupillary 
thermotherapy and plaque brachytherapy have also 
been used, but their roles are still undefined. 
Vitrectomy and enucleation are useful adjuvant 
therapies used in the management of RCHs, 
particularly in treating complex complications 
including rhegmatogenous or tractional retinal 
detachment, phthisis bulbi, neovascular glaucoma, and 
painful blind eye. Anti-angiogenic agents have been 
proposed as alternative treatments and a few studie 
have demonstrated positive responses. (Wong and 
Chew, 2008). 
Prognosis 
Because most RCHs progressively enlarge, early 
diagnosis and treatment are associated with better 
visual outcomes. Regardless, even in the setting of 
optimal treatment, more than 25% of affected patients 
show permanent visual loss with a best corrected visual 
acuity of less than 20/40 in at least one eye and about 
20% have vision less than 20/100 in at least one eye 
(Webster et al., 1999). The likelihood of visual loss  
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increases with age, secondary to the development of 
complications over time (Wong et al., 2008). A worse 
visual prognosis associated with juxtapapillary as 
compared to peripheral lesions. There is also an 
association of worse vision with increased number of 
peripheral lesions. 
Disease 
Retinal cavernous hemangioma 
Etiology 
Cavernous hemangioma of the retina are rare forms of 
congenital hamartomas that appear as solitary vascular 
tumors about 1 to 2 disc diameters in size and are 
usually in the midperiphery (Hewick et al., 2004). They 
are composed of thin-walled vascular channels with 
surface gliosis lined by non-fenestrated endothelium. 
Though sometimes transmitted in an autosomal 
dominant form, these tumors are usually sporadic 
(Sarraf et al., 2000). These may be included in the 
neuro-oculo-cutaneous (phakomatosis) syndromes, but 
the association with cerebral and cutaneous lesions is 
inconsistent (Gass, 1971). 
Epidemiology 
Although the incidence of cavernous hemangiomas of 
the retina cannot be determined because they are 
asymptomatic (Pancurak et al., 1985), women are more 
commonly affected (Patikulsila et al., 2007). The 
average age of presentation is 23 years, and the lesions 
are usually unilateral. 
Clinics 
Cavernous hemangiomas of the retina classically 
present as saccular, grapelike aneurysms that are filled 
with blood and protrude into the vitreous. Layering of 
the plasma overlying erythrocytes in the dependant p rt 
of some of the larger aneurysms can often be seen 
(Gass, 1971). While the presence of characteristic 
findings on fundoscopy is sufficient for diagnosis in 
most cases, flourescein angiography (FA) is the most 
common ancillary examination used to assist in 
diagnosis. The classic findings on FA are delayed 
perfusion of the tumor with normal retinal perfusion, 
lack of feeder or draining vessels and a lack of exudates 
(Chen, 2008). 
Pathology 
Cavernous hemangiomas of the retina are identified 
histopathologically by saccular aneurysmal dilatations 
that exhibit the anatomy of normal vessels. 
Nonfenestrated endothelial cells line the vessels, and
the basal membrane is surrounded by basement 
membrane encased pericytes, which is why there are no 
intraretinal exudates. (Messmer et al., 1984). 
Cytogenetics 
The causative gene of cerebral cavernous hemangiomas 
has been localized to 7q11-22, but it is not known if a 
gene in this region is responsible for retinal lesion . 
 
Retinal cavernous hemagioma showing characteristic "cluster-
of-grapes" appearance. 
Treatment 
Because cavernous hemangiomas of the retina are 
usually non-progressive, observation is the best 
management. No treatment has been shown to be 
effective or necessary, but photocoagulation has been 
used in some cases (Gass, 1971). The association of 
retinal cavernous hemangiomas with cerebral 
cavernous malformations in an autosomal dominant 
syndrome with variable expressivity and high 
penetrance indicates neuroimaging may be reasonable 
for patients and family members in addition to dilated 
funduscopic exams (Pancurak et al., 1985). 
Prognosis 
Most patients with localized cavernous hemangioma of 
the retina retain good vision. Rarely, visual loss 
secondary to vitreous hemorrhage or contraction of the 
preretinal membrane overlying the tumor may occur. 




Choroidal hemangioma is a benign vascular hamartoma 
that occurs most commonly in a solitary circumscribed 
form but may also present as a diffuse form (Witschel 
and Font, 1976). The cause and pathogenesis of 
circumscribed choroidal hemangioma (CCH) remains 
unclear, while diffuse choroidal hemangioma (DCH) is 
congenital and associated with Sturge-Weber 
syndrome. Sturge-Weber syndrome is a sporadic 
neurocutaneous disorder characterized by facial 
capillary malformation, leptomeningial angioma, and 
vascular ocular abnormalities (Baselga, 2004). 
Epidemiology 
Both DCH and CCH most commonly present in the 
white population, and age at diagnosis is 8 and 39, 
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respectively (Witschel and Font, 1976). There is no 
predilection based on gender or laterality. 
Clinics 
CCH often present as a dome-shaped, orange-red mass 
that may be confused with malignant lesions 
ophthalmoscopically, which increases the necessity of 
FA, ICG, and ultrasonography to aid in diagnosis. 
Ultrasonography demonstrates high internal reflectivity 
and acoustic solidity, FA is characterized by 
progressive hyperflourescence in all stages, and ICG
transitions from an early hyperfluorescence to late 
moderate hypofluorescence (Shields et al., 2001). The 
vast majority of patients with DCH have a marked 
exudative detachment, hyperopia, and involvement of 
more than half of the retina (Witschel and Fond, 1976; 
Heimann and Damato, 2009). Ophthalmoscopically, 
DCH may be more difficult to identify, making 
ancillary studies crucial for diagnosis. Patients with 
DCH have similar FA and ICG findings as those with 
CCH, but ultrasonography demonstrates diffuse 
thickening of the choroid with acoustic solidity. 
Pathology 
Histopathologically, choroidal hemagiomas have a 
complete lack of cellular proliferation of the elemnts 
of the vessel wall, indicating the nonproliferative nature 
of these lesions (Witschel and Font, 1976). CCH tend 
to have well-demarcated peripheral margins with a 
layer of compressed melanocytes and choroidal 
lamellae separating the lesion from the uninvolved 
choroid, while the DCH does not have clear margins 
separating it from the normal choroid (Witschel and 
Font, 1976). 
 
Typical presentation of a choroidal hemangioma with an orange 
elevated lesion just superotemporal to the optic disk. 
Treatment 
Observation is recommended for patients with CCH 
who are asymptomatic, while photodynamic therapy 
has become the treatment of choice for patients who are 
symptomatic. Because of the association with Sturge-
Weber syndrome, all patients with port-wine stains 
should be evaluated for DCH with a fundus 
examination, ultrasonography, and measurement of 
intraocular pressure (Baselga, 2004). Neurological 
evaluation should be performed in patients with DCH 
because of the high association of leptomeningeal 
angiomatous lesions in patients with DCH (Baselga, 
2004). Treatment for DCH consists of external or 
proton beam radiotherapy, but photodynamic therapy 
has been shown to be an effective treatment more 
recently (Bains et al., 2004). 
Prognosis 
The visual loss and visual field defects in CCH are du  
to the location of the hemagioma and retinal 
complications including subretinal fluid, macular 
edema, and macular fibrosis and atrophy. Visual 
prognosis has been poor, with greater than 50% of eyes
demonstrating a visual acuity of 20/200 or worse 
(Shields et al., 2001). DCH also has a poor visual 
prognosis as a result of the extensive choroidal 
involvement and secondary glaucoma (Grant et al., 
2008). 
To be noted 
Note 
Images republished with permission of the Journal of 
Ophthalmic Photography: The Importance of Ocular 
Photography in the Diagnosis of Ocular Tumors, Hess, 
DJ, Schefler, A. 31:2:118-128 2009. 
The authors do not have any proprietary interest or 
potential conflicts of interest in the subject matter or 
topics discussed below. 
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